Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms [177Lu]Lu-FXX489 |
Target |
Action antagonists |
Mechanism FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Ductal Carcinoma | Phase 1 | United States | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Japan | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Belgium | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Canada | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | France | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Germany | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Israel | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Italy | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Netherlands | 18 Jul 2025 | |
| Breast Ductal Carcinoma | Phase 1 | Spain | 18 Jul 2025 |





